Questcor Pharmaceuticals Inc (QCOR.OQ)
69.56USD
1:23pm EDT
$2.74 (+4.10%)
$66.82
$67.04
$69.97
$66.93
502,885
555,572
$69.97
$17.25
About
Overall
| Beta: | 0.77 |
| Market Cap (Mil.): | $3,969.88 |
| Shares Outstanding (Mil.): | 59.55 |
| Dividend: | 0.25 |
| Yield (%): | 1.50 |
Financials
| QCOR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 17.98 | 37.93 | 37.76 |
| EPS (TTM): | 3.71 | -- | -- |
| ROI: | 84.08 | 19.48 | 18.76 |
| ROE: | 115.79 | 20.17 | 19.59 |
Questcor shares touch life-high on strong growth in Acthar sales
- Shares of Questcor Pharmaceuticals Inc rose as much as 26 percent to a life-high on Wednesday, after strong sales growth for Acthar allayed concerns that reimbursement issues would restrict sales for newer uses of the drug.
Questcor profit misses estimates on weak Acthar sales
- Questcor Pharmaceuticals Inc's first-quarter profit lagged analysts' expectations as sales of its Acthar drug fell due to Medicaid reimbursement changes but the company said sales have bounced back in the current quarter.
Questcor 1st-qtr adjusted profit missed estimates
April 30 - Questcor Pharmaceuticals Inc's first-quarter profit missed Street expectations as the number of prescriptions fell for its top-selling drug, Acthar, sending its shares down about 11 percent in after market trade.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $93.85 | +0.35 |
| Pfizer Inc. (PFE.N) | $29.05 | -0.18 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.23 | +0.06 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| Abbott Laboratories (ABT.N) | $37.01 | +0.38 |
| Bayer AG (BAYGn.DE) | €89.43 | +2.08 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €76.85 | -3.32 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +28.50 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: S&P Capital IQ Factual Report
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

